Bulk Inquiry
SMU-L11
- Soluble in 0.1N HCl(aq), DMSO and EtOH
- MF: C19H24N4O
- MW: 324.42
Description
SMU-L11 is a potent and selective Toll-like receptor 7 (TLR7) agonist with an EC50 value of 24 nM against human TLR7. Activation of TLR7 stimulates innate immune signaling and promotes downstream activation of inflammatory and antiviral immune responses.
TLR7 is an endosomal pattern-recognition receptor that detects single-stranded RNA and plays a central role in innate immunity by activating NF-κB and MAPK signaling pathways, leading to production of pro-inflammatory cytokines and type I interferons. Pharmacological activation of TLR7 enhances both innate and adaptive immune responses and has become an important strategy in cancer immunotherapy, antiviral research, and vaccine adjuvant development. SMU-L11 is the racemic mixture corresponding to the more potent R-(-)-enantiomer SMU-L11-R (Axon 4465), which exhibits approximately two-fold greater activity.
Key Features
- Potent and selective human TLR7 agonist
- EC50: 24 nM
- Stimulates innate immune activation through TLR7
- Racemic mixture of the active R-(-)-enantiomer
- Useful tool for immunology and immuno-oncology research
Applications
- TLR7 signaling and innate immunity research
- Cancer immunotherapy investigations
- Antiviral immunity studies
- Vaccine adjuvant research
- Immune cell activation and cytokine signaling studies
Related Products
SMU-L11-R (Axon 4465) is available as the more potent R-(-)-enantiomer (EC50: 12 nM) and is recommended for studies requiring maximal TLR7 agonist activity.
More Information
| Parent CAS No. | 3029695-07-3 |
|---|---|
| Chemical Name | 4-Butyl-3-((perhydro-3-furyl)methyl)-3,5,8-triazatricyclo[7.4.0.02,6]trideca-1(13),2(6),4,7,9,11-hexaen-7-ylamine |
| SMILES | C1=C2C3N(CC4CCOC4)C(CCCC)=NC=3C(N)=NC2=CC=C1 |
| MFCD | N.A. |
| InChi | InChI=1/C19H24N4O/c1-2-3-8-16-22-17-18(23(16)11-13-9-10-24-12-13)14-6-4-5-7-15(14)21-19(17)20/h4-7,13H,2-3,8-12H2,1H3,(H2,20,21) |
| InChiKey | YRCAPNRYNCJHGV-UHFFFAOYNA-N |
| CID | 170836185 |
| Short Description | TLR7 agonist |
References
- Y Pan et al. Imidazoloquinoline optical isomers as TLR7 selective agonists promote macrophage activation for cancer immunotherapy. Bioorg Chem. 2025 Nov;166:109041.
- J Ou et al. Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma. J Med Chem. 2024 Mar 14;67(5):3321-3338.
